are involved in the pathogenesis of breast cancer. This study investigated polymorphisms in the promoter regions of IL-6 (-174G/C) and IL-10 (-1082G/A) through a case-control study employing 80 female subjects who were pathologically diagnosed with breast cancer. All patients received follow-up care at the Mansoura University Hospital, Mansoura, Egypt. We included another 80 females (controls) from the same population, showing no signs of malignancy. Clinicopathological features were examined in the patient groups, including the expression of estrogen and progesterone receptors, involvement of the lymph node, tumor morphology, and tumor grades. Genotyping of the promoter polymorphisms was performed using allele-specific polymerase chain reaction method. There was a significant decrease in the mean age of menarche in the patient group than that in the normal individuals. For the IL-6 -174G/C polymorphism, there was a significantly higher frequency of the CC genotype in the patients than that in the controls (odds ratio = 5.49). Furthermore, the CC genotype was significantly more prevalent among the patients who had lymph node involvement. For the IL-10 -1082G/A polymorphism, there was no difference in the distribution of genotypes among the patients and the control subjects. However, the tumor size was significantly larger in patients who were harboring the AA genotype than that in the patients who had AG or GG genotypes.
INTRODUCTION
Breast cancer is one of the most common causes of morbidity and it severely affects the general health and life expectancy of women. The incidence of breast cancer has increased to an alarming level in certain developed and developing countries (Kamangar et al., 2006; Jemal et al., 2010) . The etiological factors and pathogenesis of this disease are highly complex. In addition to numerous other mechanisms, involvement of cytokines in the progression and pathogenesis of cancer has been observed in various patient cohorts (Smyth et al., 2004; Pooja et al., 2012) . For instance, the cytokines interleukin (IL)-1, IL-4, IL-6, and IL-10 are important biomarkers for breast cancer pathogenesis and prognosis (Hefler et al., 2005) .
IL-6 is involved in various vital cellular functions such as the inflammatory response, carcinogenesis and bone metabolism (Diehl and Rincon, 2002) . In breast cancer patients, the amount of circulating IL-6 has been found to be higher than in their healthy counterparts. The amount of circulating IL-6 correlates with the severity of cancer. Furthermore, IL-6 has a likely role in the intercellular signaling between breast cancer epithelium and mesenchyme. It is also associated with the density of estrogen and progesterone receptors in these cells (Bozcuk et al., 2004) . The transcription of IL-6 is modulated by a promoter region of 303 base pairs and the -174G/ C polymorphism in the promoter sequence has been shown to be associated with pathological and clinical variables of breast cancer. This polymorphism influences in vivo expression of the gene by reducing its transcription rate and is associated with an improved therapeutic outcome in high-risk breast cancer individuals (Vickers et al., 2002; DeMichele et al., 2003) .
Another breast cancer biomarker, IL-10, is an important immune-regulatory cytokine and can potentially suppress as well as stimulate the inflammatory and immune responses (Mocellin et al., 2004; Pooja et al., 2012) . IL-10 has been shown to be overexpressed in breast cancer tumors (Venetsanakos et al., 1997) . Studies have revealed that IL-10 may affect the clinical course of cancer types and the pathogenesis of breast cancer (Howell and Rose-Zerilli, 2007) . A polymorphism in the promoter region of IL-10, -1082G/A, modulates its transcriptional landscape and thus influences the susceptibility and pathogenesis of breast cancer (Gibson et al., 2001; Hua et al., 2013) .
Nationally representative studies on the prevalence and incidence of cancer in Egypt are scarce (Ibrahim et al., 2014) . Few sporadic reports present hospital-based registries that cannot depict the overall burden of cancer in a country (Abou-Zeid et al., 2006) . Recent reports have shown that breast cancer is one of the most common cancer types in the country, succeeded only by liver cancer (Ibrahim et al., 2014) . Curiously, different biomarkers associated with certain cancer types have not been studied in Egyptian cancer patients. This case-control study investigated polymorphisms in promoter regions of IL-6 (-176G/C) and IL-10 (-1082G/A) in the Egyptian population, and evaluated whether certain genotypes at these loci are associated with breast cancer pathogenesis and clinical manifestations of cancer.
MATERIAL AND METHODS

Case-control study
The patients included 80 female individuals who were pathologically diagnosed with breast cancer and received follow-up care at Mansoura University Hospital, Mansoura (Egypt). After confirmed histopathological diagnosis, the patients were treated by conservative surgery with axillary dissection or modified radical mastectomy depending on the tumor size and nuclear grading. The healthy control individuals (N = 80) were recruited from women who were clinically free from any malignancy or breast masses and were patients at the General Surgery Department, Mansoura University Hospital (Egypt) for minor surgical operations unrelated to oncology or endocrinology. The Institutional Ethical Committee approved this study and written informed consent was obtained from all patients and controls prior to the recruitment. Demographic information including the age of menarche and menopause was acquired.
Clinicopathological investigations and immunohistochemistry
Clinicopathological features of the patient group were observed, including expression of estrogen receptor (ER), progesterone receptor (PR), involvement of the lymph node (LN), tumor size/morphology, and tumor grade. Immunohistochemistry was performed with avidin biotin complex utilizing 3, 3'-diaminobenzidine (DAB) chromogen (Dako, Glostrup, Denmark). Monoclonal mouse anti-human ER (anti-ER; 1D5, Dako) and PR (anti-PR; PgR 636, Dako) were used for the detection of receptors. Standard immunoperoxidase kits were purchased from Dako. The reagents used in the detection system includes: protein blocking agent, biotinylated secondary antibody, substrate chromogen mixture (DAB), Meyer's hematoxylin solution, streptavidin-peroxidase reagent, and mounting medium. Reagents not provided in the kits were: reagent for antigen retrieval (citrate buffer solution), working buffer solution, phosphate buffered saline, and 0.3% hydrogen peroxide in methanol.
Estrogen and progesterone receptors were categorized by positive brown nuclear staining by the method of Allred et al. (1998) . This method depends on the summation of proportion score (percent of nuclear staining: 1-5) and intensity score (intensity of staining: 1-3). The summation score ranged from 1 to 8. Scores under 2 were considered negative while scores from 3 to 8 were considered positive.
DNA extraction and genotyping
Peripheral blood samples were collected in polyethylene tubes containing EDTA and were stored at -30°C. DNA was isolated with a genomic DNA purification kit (Genta Genomic Kit; Genta Systems, Minneapolis, MN, USA). Promoter polymorphisms in IL-6 (IL-6 -174G/C; rs1800795) and IL-10 (IL-10 -1082G/A; rs1800896) were investigated using the allele-specific polymerase chain reaction (PCR) amplification protocol (primer sequences are shown in Table 1 ). PCR was performed with 300 ng DNA, 500 nM each primer, 200 mM each dNTP, and 2.5 U Taq polymerase (Amplitaq Gold; Perkin Elmer Cetus, Norwalk, CT, USA). For the amplification of the IL-6 polymorphism, the PCR conditions were as previously described (Cavet et al., 1999; Cavet et al., 2001) . PCR was carried out using 30 cycles of: 94°C for 30 s, 54°C for 60 s, and 72°C for 60 s, followed by a final extension at 72°C for 7 min. Amplification of the IL-10 polymorphism was carried out using 30 cycles of: 94°C for 30 s, 60°C for 60 s, and 72°C for 60 s, followed by a final extension at 72°C for 6 min. The amplification yields were resolved on a 3% agarose gel, which was stained with ethidium bromide and visualized under UV light.
Statistical analysis
Data were recorded and maintained as Microsoft Excel files and analyzed using SPSS17.0 (Chicago, IL, USA). The chi-square test (c 2 ) was used for comparison between groups. The Student t-test was used for quantitative data (mean ± standard deviation) to compare variables in the patient group against the control group. A level of significance set at a probability of 5% (P < 0.05).
RESULTS
A total of 80 cancer patients and 80 control individuals were recruited in this study. The characteristics of the patients and controls regarding the mean age at menarche and menopausal status are summarized in Table 2 . The mean age at menarche in the patient group was significantly lower compared to the controls (12.3 vs 13.1 years, respectively; P = 0.02; Table 2 ). However, there was no difference in the menopausal status between the two groups. For the IL-6 -174G/C polymorphism, there was a significantly higher frequency of the CC genotype in the patients with breast cancer compared to the controls [P < 0.001; odds radio (OR) = 5.49] (Table 3 and Figure 1) . Also, there was a significant association of the C allele with the patient group than that with the control group (P = 0.0003). Furthermore, for the IL-10 -1082G/A polymorphism, there was no difference in the distribution of genotypes (GG, GA and AA) or G and A alleles among the cancer patients and control individuals (OR = 1.08; P = 0.91) ( Table 3 and Figure 2 ).
The association between the IL-6 -174G/C genotypes (GG, GC, CC) and the clinicopathological features of patients was also examined. No association was observed between any of the three genotypes and the expression of ER and PR, tumor size and the grade of the tumor (Table 4) . However, LN involvement was observed to be pronounced in patients with breast cancer who had the CC genotype compared with patients with the GG or GC genotypes (P = 0.018). Likewise, for the IL-10 -1082 G/A polymorphism, genotypes were not associated with the clinical variables of patients, including expression of ER and PR, LN involvement and the grade of the tumor (Table 4) . However, the tumor size was significantly higher in the patients who were carriers of the AA genotype compared to the patients with AG or GG genotypes (P = 0.036). 
DISCUSSION
Molecular and genetics methods are increasingly becoming a part of routine medical diagnostics. PCR-based testing for polymorphisms that predispose individuals to disease has gained considerable interest among researchers and physicians studying and treating chronic diseases like cancer. Hence, the screening for mutations in candidate genes of different types of cancer has been proposed as a powerful tool in predicting the risk of morbidity (Kammerer et al., 2004) .
The proinflammatory multifunctional IL-6 is a key cytokine in humoral immune response and involves the activation of B cells (Smith et al., 2004) . The IL-6 -174G/C polymorphism has been shown to influence plasma concentrations of the cytokine in response to inflammatory stimuli. Several studies reported significant demographic differences in the distribution of -174G/C alleles, underlying the importance of population-specific references when evaluating the clinical relevance of this polymorphism (Litovkin et al., 2007) . The IL-6 -174G/C polymorphism is known to reduce gene transcription rate leading to an inhibition in the growth of tumor cells (Landi et al., 2003) . To the best of our knowledge, this is the first report on the IL-6 -174G/C polymorphism in breast cancer in an Egyptian population. Our results showed that the prevalence of the CC genotype was significantly higher among the cancer patients. These findings are consistent with Hefler et al. (2005) , who also observed a higher incidence of the CC genotype among Caucasian women with breast cancer.
Racial differences have been observed in the proportion of IL-6 -174 G/C alleles and their contribution to cancer. In a recent study, Yang et al. (2014) performed a meta-analysis based on published data and found no association between this polymorphism and prostate cancer risk in Asian and Caucasian individuals. However, the CC genotype was observed to confer increased risk of cancer among the African-American patients. In agreement with the previous study, Yeh et al. (2010) observed the incidence of colorectal cancer among patients of Taiwanese origin and investigated the association between the IL-6 -174G/C polymorphism, serum IL-6 level, and carcinoembryonic antigen (CEA) level. The prevalence of the G allele was significantly lower in the Taiwanese cohort compared to the western analogs. Furthermore, the average IL-6 and CEA levels were significantly lower in patients with the G allele. The authors concluded that ethnicity affected the status of the IL-6 -174G/C polymorphism, which consequently influenced the expression of serum IL-6 and CEA and the incidence of synchronous cancers of other origins.
In the present study, the IL-10 -1082 G/A polymorphism was not associated with breast cancer. Previously, Talaat et al. (2014) demonstrated a significant increase in the frequency of the GG genotype in Egyptian patients with Behcet's disease than that in the healthy controls. In a population based study in Northern India, Ahirwar et al. (2009) observed that GA and AA genotypes and A allele carriers of the IL-10 -1082 G/A polymorphism demonstrated an increased risk for urothelial bladder cancer. The authors suggested that the IL-10 -1082G/A polymorphism may be used as a molecular marker of urothelial bladder cancer. The IL-10 promoter polymorphism -1082G/A was also observed to exhibit a significant difference in the genotype frequency between patients and control group in Taiwanese population (Kuo et al., 2014) . Furthermore, patients carrying the G allele were found to have a higher risk for gastric cancer compared to carriers of the A allele. Li et al. (2014) conducted a meta-analysis study to examine the association between the IL-10 -1082A/G polymorphism and the risk of gastrointestinal cancer. The authors observed that the G allele significantly increased susceptibility to gastric cancer in an Asian population. In another independent meta-analysis, the IL-10 -1082 A/G polymorphism was associated with risk of type 2
